Evidence map›Paper›PMID 34377237›Full record

ArticleAmerican journal of translational research2021

Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma.

Ying-Ying Ge, Qing-Mei Zhang, Chang Liu, Xia Zeng, Wei-Xia Nong, Fang Chen, Shui-Qing Bi, Wen-Wen Guo, Bin Luo, Xiao-Xun Xie

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ying-Ying GeDepartment of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Qing-Mei ZhangDepartment of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Chang LiuDepartment of Neurosurgery, The First Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Xia ZengDepartment of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Wei-Xia NongDepartment of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Fang ChenDepartment of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Shui-Qing BiDepartment of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Wen-Wen GuoDepartment of Pathology, The People's Hospital of Guangxi Zhuang Autonomous Region Nanning 530021, People's Republic of China.
Bin LuoDepartment of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Xiao-Xun XieDepartment of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Guangxi Medical University · CNThe People's Hospital of Guangxi Zhuang Autonomous Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy of combined epigenetic drugs of decitabine (DAC), valproic acid (VPA) and trichostatin A (TSA) on immunotherapy with a murine model of hepatocellular carcinoma (HCC).

methodsDendritic cells (DCs) transduced with recombinant lentivirus expressing a cancer-testis antigen, acrosin binding protein (ACRBP), are referred to as DC/ACRBP. CD8

resultsCytotoxicity assay results revealed that DC/ACRBP-activated T cells exhibited the highest cytotoxicity against HCC cells pre-treated with triple drugs (DAC+VPA+TSA) compared with dual drugs (DAC+VPA and DAC+TSA) and single drug (DAC, VPA and TSA) respectively. Analyses of RT-PCR and immunoblotting demonstrated that the highest ACRBP expression of HCC cells was induced by the triple drugs compared with the single and dual drugs. These results indicated that DC/ACRBP-activated T cells might be ACRBP-specific lymphocytes, and the augmented cytotoxicity may be dependent on the upregulation of ACRBP expression. These assumptions were further confirmed by xenograft tumor assay. Tumor cells of mice administrated with the triple drugs exhibited increased ACRBP expression compared with those of mice without administration. As expected, DC/ACRBP-activated T cells adopted by mice injected with the triple drugs, compared with those adopted by mice without injection, remarkably impeded growth and facilitated apoptosis of tumor cells.

conclusionThese data suggested that combined treatment with DAC, VPA and TSA may enhance the anti-tumor efficacy of ACRBP-specific T cells by upregulating ACRBP expression in HCC.

Indexed as

acrosin binding proteincytotoxic T lymphocyteDecitabinehepatocellular carcinomatrichostatin Avalproic acid

Identifiers

PMID34377237
PMCPMC8340224
OpenAlexW3189171857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.